Tonix Pharmaceuticals Announces Conditional Acceptance Of Tonmya As Trade Name For TNX-102 SL For The Management Of Fibromyalgia
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has received conditional acceptance from the FDA for 'Tonmya' as the trade name for its drug TNX-102 SL, which is designed for the management of fibromyalgia.
January 29, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' trade name 'Tonmya' for TNX-102 SL has been conditionally accepted by the FDA, indicating progress in the drug's path to market.
The conditional acceptance of a trade name by the FDA is a positive regulatory step for Tonix Pharmaceuticals, suggesting that the company is moving closer to potentially marketing TNX-102 SL. This news is likely to be viewed positively by investors as it reflects progress in the drug's development and potential commercialization, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100